文献速递儿童血液肿瘤与免疫

维布妥昔单抗联合化疗治疗儿童难治或复发经典型霍奇金淋巴瘤10例分析

[Analysis of 10 cases of brentuximab vedotin combined with chemotherapy in the treatment of children with refractory and or relapsed classic Hodgkin lymphoma].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2024-01-01

回顾性分析2021年10月至2023年8月北京儿童医院10例难治或复发经典型霍奇金淋巴瘤患儿的临床资料,评估维布妥昔单抗(BV)联合化疗的有效性和安全性。10例患儿均接受至少2周期BV联合化疗,9例达到完全缓解,所有患儿均无事件生存;3级以上不良事件以骨髓抑制为主,均与化疗相关且未影响序贯治疗。

要点

  • 10例难治或复发经典型霍奇金淋巴瘤患儿接受BV联合化疗后均有效,9例达完全缓解。
  • BV剂量按化疗强度调整:每3周1次为1.8 mg/kg,每2周1次为1.2 mg/kg。
  • 3级以上不良事件以骨髓抑制为主,均与化疗相关,未影响序贯治疗。

核心结论

  • 维布妥昔单抗联合化疗治疗儿童难治及复发CD30阳性经典型霍奇金淋巴瘤早期显效,安全性可耐受。

研究设计与样本

  • 回顾性分析2021年10月至2023年8月首都医科大学附属北京儿童医院诊治的10例难治或复发经典型霍奇金淋巴瘤患儿临床资料。
  • 10例患儿均接受至少2周期BV联合化疗,每2周期评估缓解情况,随访至2024年5月31日。
  • BV剂量根据化疗药物强度决定:每3周1次应用BV者剂量为1.8 mg/kg,每2周1次应用BV者剂量为1.2 mg/kg。

主要发现

  • 10例患儿中男7例、女3例,年龄5.3~16.9岁,难治6例、复发4例。
  • 病理类型:结节硬化型6例、混合细胞型2例、富于淋巴细胞型1例、淋巴细胞消减型1例。
  • 临床分期:Ⅳ期5例、Ⅲ期5例;既往治疗以化疗为主,4例曾接受放疗,1例曾接受PD-1抗体治疗。
  • 随访时间9~27个月,共记录43周期单独应用BV或BV联合化疗,疗程数2~10个。
  • 10例患儿均无事件生存,9例持续完全缓解;BV均顺利完成输注。

关键数值与推荐

  • 共记录到28例次患儿发生3级以上不良事件,以骨髓抑制为主,均与化疗相关,均未影响序贯治疗。

临床怎么用

  • 对于儿童难治或复发经典型霍奇金淋巴瘤,可考虑采用BV联合化疗方案,并根据化疗强度选择BV剂量。
  • 治疗期间需监测输注反应及不良事件,尤其是骨髓抑制,但本组不良事件未影响序贯治疗。

局限性

  • 本研究为单中心回顾性分析,样本量仅10例,随访时间9~27个月,结论需更大样本和更长随访验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of CD30 antibody-drug conjugates (ADC) brentuximab vedotin (BV) combined with chemotherapy in children with refractory or relapsed classic Hodgkin's lymphoma (R/R cHL). Methods: Clinical data (including age, gender, B symptoms, clinical stage, previous treatment, etc.) of the 10 R/R cHL children diagnosed and treated at Beijing Children's Hospital Affiliated to Capital Medical University from October 2021 to August 2023 were analyzed retrospectively. According to the different intensity of chemotherapy drugs, the dose of BV applied in the same course of treatment was 1.8 mg/kg for BV applied once every 3 weeks, and 1.2 mg/kg for BV applied once every 2 weeks. All 10 patients received at least 2 cycles of BV combined with chemotherapy and were evaluated every 2 cycles. The patients were followed up until May 31, 2024. The infusion reactions and adverse reactions after treatment were recorded. Results: In all 10 patients, there were 7 males and 3 females, the age ranged from 5.3-16.9 years, and there were 6 cases of refractory and 4 cases of relapsed. There were 6 cases of nodular sclerosis type, 2 cases of mixed cell type, 1 case of lymphocyte-rich type, and 1 case of lymphodepletion type. There were 5 cases of stage Ⅳ and 5 cases of stage Ⅲ. Previous treatment was mainly chemotherapy, 4 cases received radiotherapy and 1 case received programmed cell death protein 1 (PD-1) antibody therapy. The follow-up time ranged from 9 to 27 months. A total of 43 courses with 49 doses of BV alone or combined with chemotherapy were recorded, and the number of courses was 2 to 10 times. All 10 children responded to the treatment, and 9 achieved complete remission. BV infusion was successfully completed in all cases. A total of 28 cases of grade 3 or above adverse events were recorded, mainly myelosuppression, all of which were related to chemotherapy and did not affect sequential treatment. Conclusion: Brentuximab vedotin has demonstrated efficacy and a tolerable safety profile in the treatment of refractory and relapsed CD30-positive Hodgkin's lymphoma in children. 目的: 评估CD30抗体-药物偶联物(ADC)维布妥昔单抗(BV)联合化疗治疗儿童难治或复发经典性霍奇金淋巴瘤(R/R cHL)的有效性和安全性。 方法: 回顾性分析2021年10月至2023年8月在首都医科大学附属北京儿童医院诊治的10例R/R cHL患儿的临床资料(包括年龄、性别、B症状、临床分期、既往治疗情况等),10例患儿均接受至少2周期BV联合化疗,根据化疗药物强度的不同决定与其同疗程应用的BV剂量,每3周1次应用BV者剂量为1.8 mg/kg,每2周1次应用BV者剂量为1.2 mg/kg。每2个周期评估患儿缓解情况,随访至2024年5月31日。记录用药期间有无输注反应及用药后的不良反应。 结果: 10例患儿中男7例,女3例;年龄5.3~16.9岁;难治6例,复发4例;结节硬化型6例,混合细胞型2例,富于淋巴细胞型1例,淋巴细胞消减型1例。临床分期Ⅳ期5例,Ⅲ期5例。既往接受治疗以化疗为主,4例患儿曾接受放疗,1例患儿曾接受程序性死亡受体1(PD-1)抗体治疗。随访时间为9~27个月,共计43周期单独应用BV或BV联合不同方案化疗,疗程数为2~10个,10例患儿均无事件生存,9例患儿持续完全缓解。BV均顺利完成输注,共记录到28例次患儿发生3级以上的不良事件,以骨髓抑制为主,均与化疗相关,均未影响序贯治疗。 结论: BV治疗儿童难治及复发CD30阳性霍奇金淋巴瘤的早期显效,安全性可耐受。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li N, Li Y, Zhou CJ, et al. [Analysis of 10 cases of brentuximab vedotin combined with chemotherapy in the treatment of children with refractory and or relapsed classic Hodgkin lymphoma]. Zhonghua Er Ke Za Zhi. 2024. PMID: 39039881. doi:10.3760/cma.j.cn112140-20240615-00399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。